Recursion Pharmaceuticals Navigates Tumultuous Transition Following Landmark Acquisition

The year 2025 has been a period of intense transformation for Recursion Pharmaceuticals, a biotechnology firm whose shareholder base expanded to include former Exscientia investors following a late-2024 acquisition. The combined entity, a provider of AI-driven discovery platforms, now grapples with strategic realignment amidst significant leadership changes, workforce reductions, and emerging commercial validation.

Marking a definitive shift in corporate direction, Recursion announced on November 5, 2025, that co-founder Chris Gibson would step down from his role as Chief Executive Officer effective January 1, 2026. He is slated to assume the position of Chairman of the Board. Succeeding him will be Najat Khan, the company’s current Chief Commercial and Chief R&D Officer. This Read more...